Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 17;12(6):842. doi: 10.3390/biom12060842

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(A) BAX/Bcl2 ratio in control keratinocytes treated with CBD (4 μM) or AEA (4 μM) or irradiated with UVB (60 mJ/cm²) as well as cells irradiated with UVB and treated with CBD or AEA (in the same concentrations). (B) BAX/Bcl2 ratio in keratinocytes after treatment with 20 μM celecoxib alone and with CBD(4 μM) or AEA(4 μM) or irradiated with UVB (60 mJ/cm²) as well as cells irradiated with UVB and treated with CBD or AEA (in the same concentrations). (a)—statistically significant differences between keratinocytes treated with CBD, AEA, UVB, UVB + CBD, AEA + UVB and non-treated cells as well as keratinocytes treated with CBD + celecoxib, AEA + celecoxib, UVB + celecoxib, UVB + CBD + celecoxib and AEA + UVB+ celecoxib and cells treated only with celecoxib; p < 0.05; (b)—statistically significant differences between keratinocytes treated with UVB + CBD, UVB + AEA, UVB + CBD + celecoxib, AEA + UVB + celecoxib and irradiated with UVB p < 0.05; (c)—statistically significant differences between keratinocytes treated with celecoxib and corresponding keratinocytes not treated with celecoxib.